Answers are grounded in this paper and cite their sources.
In infants with type 1 spinal muscular atrophy, treatment with oral risdiplam led to an increased expression of functional SMN protein in the blood. (Funded by F. Hoffmann-La Roche; ClinicalTrials.gov number, NCT02913482.).
No takes yet. Share an insight, caveat, or question.
Baranello et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: